About TICM

Why This Institute Exists

Promising mobility and cardiopulmonary technologies routinely stall, not because they fail, but because the evidence infrastructure was never designed to support them. TICM was founded to close that gap.

Origin

A Structural Problem Required a New Institution

The evidence has not kept pace with the technology. Exoskeletons are lighter, wearable respiratory monitors more precise, and pulmonary rehabilitation more sophisticated than it was a decade ago. But studies still enroll too slowly, measure the wrong things, and produce fragments instead of foundations.

Studies enroll too slowly because trial networks were built for other therapeutic areas. Endpoints measure what is publishable rather than what persuades regulators, payers, and health systems. Evidence accumulates in fragments: enough for a poster session, not enough to change clinical practice.

TICM was not adapted from an existing academic program. It was founded from the ground up to address the specific structural failures in how evidence gets generated for cardiopulmonary mobility technologies.

Institutional Context

TICM is an initiative of Texas Pulmonary Foundation, giving the institute a nonprofit parent organization and a clearer institutional base as it develops its translational platform.

Nonprofit

501(c)(3) Research Institute

Houston, TX

Clinical Research Base

Translational

Evidence Designed to Travel

Mission

Generating Evidence That Reaches Patients

TICM generates clinically grounded, decision-useful evidence for technologies and interventions in cardiopulmonary mobility, so promising approaches can move from pilot to practice.

The institute exists at the intersection of wearable robotics, cardiopulmonary rehabilitation, and real-world physiologic validation. Its research is designed to serve the full evidence journey: from feasibility through publication to regulatory, payer, and clinical adoption decisions.

Our Model

Three Structural Advantages

Every design choice at TICM exists to remove a specific barrier between a promising technology and credible evidence.

01

Clinical Access

TICM is embedded within active cardiopulmonary care. The populations most relevant to mobility technology research are patients we see in clinical practice, not populations we recruit through referral chains.

02

Lean Study Design

Studies designed at the scale and pace appropriate to where a technology actually is. Smaller initial commitments. Evidence structured to inform the next decision, not just the next publication.

03

Endpoints That Persuade

Functional capacity. Cardiopulmonary performance. Real-world mobility outcomes. Selected for their utility across peer review, regulatory submission, payer evaluation, and clinical adoption.

Differentiation

What TICM Is Not

TICM is not a contract research organization. It is not a hospital marketing initiative. It is not an academic department with a website.

Traditional CRO / Academic Dept

  • xEvidence optimized for publication
  • xTrial networks built for other areas
  • xSite activation takes months
  • xStudies don't build on each other
  • xEndpoints miss regulatory context

TICM

  • +Decision-grade evidence: regulatory, payer, clinical
  • +Embedded in active cardiopulmonary care
  • +Direct patient access from day one
  • +Each study sets up the next
  • +Endpoints selected to travel across contexts
Get Started

Built for This Conversation

If your organization is developing, funding, or advancing technologies in cardiopulmonary mobility, TICM was designed for this kind of collaboration.